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Despite substantial progress in control in endemic settings,
tropical parasitic diseases such as malaria, leishmaniasis and
American trypanosomiasis (Chagas disease) continue to affect
millions of people worldwide [1–3]. In addition to representing
a long-lasting burden in tropical countries, in recent decades
these conditions have become a challenge for clinicians in
non-endemic settings, as a result of increasing travel and
migration [4–6]. Finally, the increasing number of immuno-
compromised individuals in tropical environments—interna-
tional travellers or local populations of emerging economies
with immunosuppressive conditions or treatment—makes the
global picture even more complex [7,8]. Indeed, the multiple
and reciprocal interactions between parasites and immunity
are still to be fully elucidated, and the impact of immunosup-
pression not only on infection rate and clinical presentation,
but also on the management and even global epidemiology of
parasitic diseases, is being better recognized, with the speciﬁc
issue of drug–drug interactions increasingly addressed in
recent research.
This themed issue of Clinical Microbiology and Infection is
aimed at appraising the current knowledge and newly
identiﬁed gaps in the epidemiology and management of three
major tropical parasitic diseases among immunosuppressed
individuals. First, although malaria may seem to be less
associated with immunosuppression (except in patients with
asplenia [9]), Van Geertruyden describes the multiple,
complex and mutual epidemiological and clinical interactions
between this condition and the human immunodeﬁciency
virus (HIV) epidemic in sub-Saharan Africa (Van Geertruy-
den, Clin Microbiol Infect, April 2014), as it has been also
observed in HIV-infected travellers [10,11]. In the second
article, van Griensven et al. comprehensively review the
clinical and therapeutic impact of various immunosuppressive
conditions on leishmaniasis in different epidemiological con-
texts, such as HIV infection in East Africa or immunomod-
ulating agents in Europe (van Griensven et al., Clin Microbiol
Infect, April 2014). Finally, Lattes and Lasala share their
experience in preventing and treating Chagas disease in the
growing population of South American immunosuppressed
individuals (Lattes and Lasala, Clin Microbiol Infect, April 2014).
Hopefully, readers will become aware that the recent trends
in mobility, aging and susceptibility of the global population
open new challenging chapters in the long history of human–
parasite confrontation.
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